Navigation Links
Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
Date:1/26/2009

of ENBREL to wholesaler distribution in that quarter.

Worldwide sales of Sensipar(R) (cinacalcet) increased 20 percent to $153 million in the fourth quarter of 2008 versus $128 million during the fourth quarter of 2007. For the full year, Sensipar sales were $597 million in 2008 versus $463 million in 2007, a 29 percent increase. This growth was principally driven by demand.

Vectibix(R) (panitumumab) sales for the fourth quarter were $46 million as compared to $33 million in the fourth quarter of 2007. Sales growth for the fourth quarter was driven by international demand as a result of the recent launch of Vectibix in Europe, partially offset by a decline in U.S. demand. For the full year, worldwide Vectibix sales were $153 million in 2008 versus $170 million in 2007, a 10 percent decrease. This decrease was primarily driven by a decline in segment share.

Operating Expense Analysis on an Adjusted Basis:

Cost of sales decreased 3 percent to $549 million in the fourth quarter of 2008 versus $565 million in the fourth quarter of 2007. This decrease was due to lower cost ENBREL partially offset by higher sales volume and excess capacity charges.

For the full year, cost of sales was $2,193 million in 2008 versus $2,255 million in 2007, a decrease of 3 percent. The decrease for the full year was primarily driven by lower excess inventory write-offs and lower cost ENBREL, offset by higher sales volume and excess capacity charges.

Research & Development (R&D) expenses were $770 million in the fourth quarter of 2008 versus $785 million in the fourth quarter of 2007, a decrease of 2 percent. The reduced spend was mainly driven by lower late-stage clinical trial costs, including denosumab, as well as the benefit of our licensing agreement with Takeda in Japan. These decreases were partially offset by higher clinical trial spend for our
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
2. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
3. Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
4. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
5. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
6. BioMed Realty Trust Declares Fourth Quarter 2008 Common Stock and Preferred Stock Dividends
7. Martek Announces Fourth Quarter and FY 2008 Financial Results
8. Martek to Announce Fourth Quarter and Fiscal Year 2008 Results
9. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... The synthetic ... to get such derivatives as ethylbenzene, a precursor to styrene, used to make ... automotive industry for the production of tyres and other components. Thus, growth in ...
(Date:8/3/2015)... -- E-QURE Corp. (OTCQB: EQUR), a Delaware ... Therapy device ("BST Device"), a new and novel electrotherapy ... wounds, today announced that the Company has signed its ... in medical devices, for the marketing and distribution of ... years old, sales, marketing and distribution company in ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation ... its comprehensive line of analytical laboratory equipment. With optimized features, such as PTFE-coated ... a chemically resistant and maintenance-free solution for a broad range of vacuum filtration ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC ... method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based ...
Breaking Biology Technology:World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Sterlitech Launches New Line of Vacuum Pumps 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... other multi-resistant organisms, PRINCETON, N.J., May 2 ... of advanced wound care products, today,announced that the ... of top wound,care studies, devoted a section to ... The article, "Spotlighting the Top-10,Research Findings in Wound ...
... Finesse Solutions, LLC,Santa Clara, CA, a manufacturer of ... announced the release of TruViu(TM),PLSS, a vessel utility ... The PLSS package expands on the RDPD system ... enclosures. TruViu(TM) PLSS,consists of an I/O tower, a ...
... May 1 Masimo Corporation,(Nasdaq: MASI ), the ... is scheduled to present at the Deutsche Bank 33rd,Annual ... MA,on Tuesday, May 6, 2008 at 9:30 a.m. ET. ... Web cast of the presentation will be available on ...
Cached Biology Technology:Skin & Aging Article Finds Derma Sciences MEDIHONEY(TM) Helps to Promote Healing Where Antibiotics Fail 2Skin & Aging Article Finds Derma Sciences MEDIHONEY(TM) Helps to Promote Healing Where Antibiotics Fail 3Skin & Aging Article Finds Derma Sciences MEDIHONEY(TM) Helps to Promote Healing Where Antibiotics Fail 4Finesse Solutions Introduces the TruViu(TM) PLSS System 2Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference 2
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:7/2/2015)... July 2, 2015 Fingerprint Cards has ... FPC1145 and FPC1155 from the distributor World Peace Industrial Group ... distributors in Asia . Deliveries are planned ... will be used by smartphone manufacturers in Asia ... in the communicated revenue guidance of approximately 2,200 MSEK for ...
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... of Medicine report in a new study that they have ... myelin, the fatty insulation around nerve cells that ensures swift ... in the September 1, 2005, issue of the journal Neuron, ... such as multiple sclerosis, which are associated with damage to ...
... University of Delaware researchers are opening a new front ... nanotechnologies for cancer detection and treatment and introducing a ... tumors. , Balaji Panchapakesan, assistant professor of electrical ... the discoveries in the journals NanoBiotechnology and Oncology Issues. ...
... the January 2006 issue of Nature Biotechnology, researchers led ... Center have devised a novel strategy that uses stem ... sickle cell disease (SCD) in human cells. This research ... correct this debilitating blood disease using RNA interference technology. ...
Cached Biology News:Scientists discover the molecular switch for nerve cells' insulating jelly rolls 2University of Delaware researchers develop cancer 'nanobomb' 2University of Delaware researchers develop cancer 'nanobomb' 3University of Delaware researchers develop cancer 'nanobomb' 4Sickle cell disease corrected in human models using stem cell-based gene therapy 2
... foil heat sealing material is suitable ... a screw down heated lid), especially ... useful method for sample retrieval. Multiple ... existing seal. Ideal for compound management ...
...
...
... fully automated solution for cell culture ... for cell-line maintenance, expansion, harvesting and ... built upon standard, industry proven components: ... configuration capable of both rapid bulk ...
Biology Products: